Merck: new cancer treatments and the Keytruda patent cliff
FROM THE WIRE · FINANCE.YAHOO.COM
A Growing Franchise With an Expiration Date Merck & Co., Inc. (NYSE:MRK) is trying to extend its oncology leadership before competition threatens its largest earnings engine. Keytruda and Keytruda Qlex produced $8.4 billion of second-quarter 2026 sales, about half the company's…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA Dutch court ordered a halt to sales of subcutaneous Keytruda in eight European markets, weighing on a key revenue franchise.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Keytruda and Keytruda Qlex produced 8.4 billion dollars of sales in the second quarter of 2026.
- 02That is about half of the company's 16.6 billion dollars worldwide revenue.
- 03Reuters reported that a Dutch patent court ordered a halt to sales of the subcutaneous formulation in eight European markets.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Merck & Co., Inc.148.38 USD+0.29%today +3.31%Negative Moderna, Inc.240.60 USD+0.70%today +6.04%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets